Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia
| Autor: | Isabelle Cano, Hassan Farhat, Stéphanie Ghez, Marc Spentchian, Christine Terré, Florence Beckeriche, Florence Oberkampf, Pascale Cony-Makhoul, Isabel Garcia, Diane Lara, David Ghez, Stéphane de Botton, Anne Laure Taksin, Omar Benbrahim, Philippe Rousselot, Mathilde Ruggiu, Sophie Rigaudeau, Noémie de Gunzburg, Victoria Raggueneau |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Myeloid medicine.drug_class Kaplan-Meier Estimate Tyrosine-kinase inhibitor 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Transplantation Homologous CD135 Protein Kinase Inhibitors Neoplasm Staging business.industry Hematopoietic Stem Cell Transplantation Myeloid leukemia Hematology medicine.disease Combined Modality Therapy Hematologic Response Haematopoiesis Treatment Outcome medicine.anatomical_structure 030220 oncology & carcinogenesis Cytogenetic Analysis Leukemia Myeloid Chronic-Phase Azacitidine Female business Tyrosine kinase Biomarkers 030215 immunology Chronic myelogenous leukemia |
| Zdroj: | Leukemia & Lymphoma. 59:1659-1665 |
| ISSN: | 1029-2403 1042-8194 |
| DOI: | 10.1080/10428194.2017.1397666 |
| Popis: | Although the tyrosine kinase inhibitor (TKI) era has brought great improvement in outcome in chronic myelogenous leukemia (CML), prognosis of accelerated phase or myeloid blast crisis patients or of de novo Philadelphia chromosome-positive acute myeloid leukemia remains poor. We conducted a retrospective study on patients with advanced phase disease treated with a TKI and azacytidine. Sixteen patients were eligible. Median age was 64.9 years, the median number of previous therapies was 2.5 lines, and median follow-up was 23.1 months. Hematologic response (HR) rate was 81.3%. Median overall survival (OS), event free survival and relapse-free survival (RFS) were 31.5, 23.3, and 32.2 months, respectively. All except one patient were treated as out-patients after the first cycle. Five patients were bridged to allogenic hematopoietic stem cells transplant. The combination of a TKI and azacytidine is a safe and efficient regiment for patients with CML patients in advanced phases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|